TPO and fatty liver disease: Although topiroxostat inhibited both XOR activity and XOR-dependent purine catabolism in liver, the extent of hepatic steatosis and fibrosis was not different between the CDAHFD/TPX (-) and CDAHFD/TPX (+) groups (Supplemental Figure 3, C and D).